Alberto Volta-Dalla
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.
Journal: European urology oncology
Published: December 16, 2024
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Journal: Prostate cancer and prostatic diseases
Published: November 17, 2024
Fat Fraction Extracted from Whole-Body Magnetic Resonance (WB-MR) in Bone Metastatic Prostate Cancer: Intra- and Inter-Reader Agreement of Single-Slice and Volumetric Measurements.
Journal: Tomography (Ann Arbor, Mich.)
Published: May 02, 2024
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Journal: European urology
Published: March 10, 2024
Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis.
Journal: Case reports in oncology
Published: October 17, 2023
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Journal: eLife
Published: September 10, 2023
Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients.
Journal: Current oncology reports
Published: August 01, 2023
Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Journal: Journal of endocrinological investigation
Published: April 23, 2023
Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib.
Journal: In vivo (Athens, Greece)
Published: November 02, 2022
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.
Journal: Endocrine
Published: June 23, 2022
Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 08, 2022
Last Updated: 09/26/2026